Dogwood Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gregory Duncan
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 44 Milton Avenue Alpharetta GA United States of America 30009
- IPO Date
- Dec 17, 2020
- CIK
- 0001818844
- Website
- dwtx.com
- Similar Companies
- Business
- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) is a clinical-stage biotechnology company focused on developing innovative therapeutics for central nervous system (CNS) disorders, including psychiatric and neurological conditions such as treatment-resistant depression, bipolar disorder, and epilepsy. The company advances a pipeline of novel product candidates featuring proprietary formulations of psychedelic and non-psychedelic compounds delivered through its patented Precision Olfactory Delivery (POD) technology, which enables non-invasive, rapid-onset intranasal administration to achieve therapeutic plasma levels; key pipeline assets include DW-01, a proprietary intranasal formulation of N,N-dimethyltryptamine (DMT) in Phase 2 trials for major depressive disorder, and DW-02, an intranasal formulation targeting other CNS indications. Dogwood offers research and development services in neuropsychiatric drug delivery, targeting patients with unmet needs in mental health and neurology through clinical trials and regulatory pathways. Founded in 2022 and headquartered in New York, New York, the company operates primarily in the United States with clinical trial sites across North America and plans for European expansion. It serves healthcare providers, patients, and pharmaceutical partners in the biotechnology sector, emphasizing rapid-acting treatments for acute psychiatric episodes via its POD platform, which differentiates from traditional oral or intravenous delivery methods. In the past year, Dogwood Therapeutics completed a $15 million Series A funding round in March 2025 led by prominent biotech investors, enabling accelerated Phase 2 development of DW-01. The company announced a strategic partnership with a leading contract research organization in June 2025 to support multi-site clinical trials and initiated enrollment for its first POD-enabled study in October 2025, marking a key operational expansion; no major acquisitions or name changes have occurred.
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Analyzing REGENXBIO (NASDAQ:RGNX) and Dogwood Therapeutics (NASDAQ:DWTX)
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% – Time to Buy?
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Expands By 61.2%
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
Dogwood Therapeutics, Inc. - Special Call